Form 4: Xenon Pharmaceuticals Director Gary Patou Executes Stock Options and Sells Shares

Xenon Pharmaceuticals director Gary Patou exercised stock options and sold shares on November 22, 2024, resulting in a net decrease in his direct holdings.

Summary

• Gary Patou, a director at Xenon Pharmaceuticals, engaged in multiple transactions involving the company's common shares on November 22, 2024.
• He exercised stock options to acquire 3,500 shares at $7.38 and 3,086 shares at $13.48.
• He also sold 649 shares at $39.80, 2,851 shares at $41.11, 1,046 shares at $39.80 and 2,040 shares at $41.05.
• Following these transactions, his direct holdings decreased to 23,573 shares, while he also has indirect holdings of 4,902 shares through a family trust.
• The stock options exercised are fully vested and exercisable.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions. While the sale of shares could be seen as slightly negative, the exercise of options is a positive sign. Overall, the sentiment is neutral.

Positives

• The exercise of stock options indicates confidence in the company's future prospects by the director.
• The transactions were executed under a pre-arranged plan, suggesting they were not based on any new material information.

Negatives

• The sale of a significant number of shares by a director could be perceived negatively by the market.
• The net decrease in direct holdings may raise concerns about the director's long-term commitment to the company.

Risks

• The market may react negatively to the director's share sales, potentially impacting the stock price.
• Further sales by the director could put additional downward pressure on the stock.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders engage in transactions involving their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Form 4 filings are a standard practice for all publicly traded companies in the US, and this filing is consistent with those requirements.
• The transactions are typical for executives who receive stock options as part of their compensation package.
• The sale of shares after exercising options is a common practice to realize gains and manage personal finances.

Stakeholder Impact

• Shareholders may react to the director's share sales, potentially impacting the stock price.
• The transactions do not directly impact employees, customers, or suppliers.

Key Dates

Keywords

Xenon Pharmaceuticals, insider trading, stock options, share sales, Form 4, Gary Patou, director, equity